Stylus now launching in the U.S. at American Rhinologic Society (ARS) and American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNSF) annual meetings
Sunnyvale, CA – September 8, 2022 – Aerin Medical Inc., a company that provides Ear, Nose and Throat (ENT) physicians with non-invasive solutions to treat chronic nasal conditions, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and launch of a next-generation RhinAer® stylus. RhinAer is a non-invasive, temperature-controlled radiofrequency technology that durably treats the causes of rhinorrhea (runny nose), post-nasal drip and congestion associated with chronic rhinitis in a single session. The new RhinAer is designed to provide physicians with improved visualization, easier access and tissue apposition, especially in patients with narrow nasal airways.
The new RhinAer stylus will be available for physicians to preview in the Aerin Medical booth at the American Rhinologic Society (ARS) annual meeting September 9-10, as well as at the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNSF) annual meeting September 11-13. Both meetings will take place in Philadelphia.
“The new RhinAer stylus gives me confidence that I can access and treat the posterior nasal nerve area more effectively,” said Dr. Randall Ow, otolaryngologist at Sutter Health in Sacramento and the first physician in the world to use the device on a patient. “This newer generation RhinAer allows me to confidently treat multiple target areas, in the office setting, even in very challenging anatomy.”
The new RhinAer is the result of close collaboration and feedback between Aerin Medical and otolaryngologists, with multiple enhancements intended to make the device easier to use. RhinAer’s new lower-profile stylus has been modified with a slimmer shaft and tip to improve visualization and access. Additionally, the tip now tilts backward 10 degrees, and the shaft is more malleable, which allows for easier tissue apposition during procedures.
“As a company that is committed to innovation, Aerin Medical relentlessly strives to meet the needs of physicians and their patients,” said Matt Brokaw, CEO of Aerin Medical. “We listened closely to the otolaryngology community in developing the new RhinAer. Based upon our discussions, rigorous testing and physician feedback, we are confident that the next-generation RhinAer stylus enhancements will be well-received.”
Rhinitis, or inflammation of the mucous membrane of the nose, can include symptoms such as runny nose, congestion, itching, sneezing, coughing, and post-nasal drip. Chronic rhinitis, when symptoms last more than four consecutive weeks, can be challenging to treat. With RhinAer, the stylus is inserted into the nasal airway to directly interrupt nerve signals and to help reduce chronic rhinitis symptoms. RhinAer has been clinically proven in multiple studies to durably treat chronic rhinitis symptoms. A recent long-term clinical study of RhinAer showed that 88.2% of patients positively responded to treatment at 24 months, defined as a ≥30% improvement in chronic rhinitis symptoms compared to baseline.
For more information about RhinAer, please visit www.RhinAer.com.
Additional Activities at AAO-HNSF Annual Meeting
The company will host an educational event at AAO, “In-Office Treatment Advances for Nasal Airway Obstruction and Chronic Rhinitis: Dialogue and Case Study Debate,” the morning of Monday, September 12. This symposium will be moderated by Troy D. Woodard, M.D., professor at Cleveland Clinic Lerner College of Medicine at Case Western University, and will feature three panel members: Jivianne Lee, M.D., associate professor in the Department of Head and Neck Surgery at the UCLA David Geffen School of Medicine; Joseph Han, M.D., professor, chief of the Division of Rhinology & Endoscopic Sinus and Skull Base Surgery, and chief for the Division of Allergy at Eastern Virginia Medical School; and Mary G. Ashmead, M.D., otolaryngologist at Texas Ear, Nose and Throat Specialists. They will discuss a variety of cases and share their experiences and preferred treatment modalities using Aerin Medical’s RhinAer and VivAer®.
For more information about this event or Aerin Medical’s other activities at these meetings, contact firstname.lastname@example.org.
Using temperature-controlled, radiofrequency technology, RhinAer features a thin, wand-like stylus that is inserted via the nostril to deliver precise therapeutic benefits, while sparing surrounding tissues. RhinAer directly disrupts the posterior nasal nerve (PNN) that triggers excessive mucus production, treating an underlying cause of chronic rhinitis. RhinAer provides ENT physicians with a comprehensive solution for the treatment of chronic rhinitis, addressing sources of rhinorrhea (runny nose) and congestion. The procedure can be performed with a local anesthetic during an office visit, with no incisions, minimal to no downtime, and little discomfort. RhinAer initially received FDA 510(k) clearance in December 2019 and CE Mark in 2020. For more information, visit www.RhinAer.com..
VivAer is a non-invasive technology that uses patented, temperature-controlled radiofrequency energy and is clinically demonstrated to provide long-term relief from nasal obstruction. VivAer features a thin, wand-like stylus that attaches to a console. The stylus is inserted via the nostril to gently remodel the nasal tissue and improve airflow. VivAer does not involve any cutting, freezing, or removal of nasal tissue or bone. Treatment with VivAer may be performed during an office visit with local anesthesia. Patients typically experience little discomfort with minimal to no downtime and are often able to return to normal activities immediately following treatment.* The VivAer Stylus received CE Mark in 2016 and FDA 510(k) clearance in December 2017. For more information, visit www.VivAer.com.
*Individual results may vary.
About Aerin Medical
Aerin Medical is a privately held, venture-backed company, with U.S. offices in California and Texas. Aerin’s mission is to provide ENT physicians with non-invasive solutions for the treatment of chronic nasal conditions. The company’s products, VivAer® for nasal airway obstruction and RhinAer® for chronic rhinitis, leverage Aerin’s proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients’ symptoms with in-office procedures performed with local anesthetic. More than 60,000 patients have been treated with Aerin Medical products to date. For more information, please visit www.aerinmedical.com and follow Aerin Medical on Facebook, Twitter, Instagram, LinkedIn and YouTube.
Or submit your inquiry below and we’ll get back you within one business day.